Last reviewed · How we verify

NCT04806789

Plasma Sodium: a Predictor of Perforation in Acute Appendicitis. (The NAP-study)

Completed Last updated 27 November 2024
What this trial tests

trial in Acute Appendicitis in 451 participants. Completed in 25 November 2024.

Timeline
1 June 2021
Primary endpoint
25 November 2024
25 November 2024

Quick facts

Lead sponsorUrban Fläring
StatusCompleted
Study typeOBSERVATIONAL
Enrollment451
Start date1 June 2021
Primary completion25 November 2024
Estimated completion25 November 2024
Sites1 location across Sweden

Conditions studied

Sponsor

Urban Fläring

Who can join

Adults 1 to 15, any sex, with Acute Appendicitis or Children, Only. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical prospective diagnostic accuracy study assesses plasma sodium concentration using blood gas analysis at the emergency department in children, age 1-15 years, with suspected acute appendicitis. The overall assumption is that using plasma sodium as a biomarker, a cut-off value of \<136 mmol/L will differentiate perforated from non-perforated acute appendicitis. In addition, traditionally used clinical diagnostic variables as well as radiology used in the diagnosis of acute appendicitis will also be obtained. Histopathology will be used to define if the appendix is perforated or not.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Appendicitis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing